<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551694</url>
  </required_header>
  <id_info>
    <org_study_id>HMA110541</org_study_id>
    <nct_id>NCT00551694</nct_id>
  </id_info>
  <brief_title>A Second Study to Determine the Effect of GSK256073A on HVTs</brief_title>
  <official_title>A Second Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single and a Repeat Oral Dose of GSK256073A in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of single and repeat doses of GSK256073
      with placebo in HVT subjects that have been administrated GSK256073 in the HMA107787 study
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs, 12-Lead ECG, vital signs, nursing/physician observation, safety lab tests, flushing throughout the study.</measure>
    <time_frame>throughout the study.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC and Cmax</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measures of accumulation ratios throughout the study (Ro, Rp, and Rs)[Period 2]</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax, t½, Ae, and CLr , Cmax, ss, Ct, t½, Ae, CLr, and accumulation ratios throughout the study</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD response: NEFA and TG (6 and 24 hours post- dose), LDL, HDL, ApoA1, ApoA2, Apo B and Lp(a) on Days 1, 14, and 15.</measure>
    <time_frame>Days 1, 14, and 15</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Dyslipidaemias</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK256073A tablets</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy as determined by a responsible physician, based on a medical evaluation
             including history, physical examination, laboratory tests, cardiac monitoring. A
             subject with a clinical abnormality or laboratory parameters outside the reference
             range for the population being studied may be included only if the Investigator
             considers that the finding will not introduce additional risk factors and will not
             interfere with the study procedures

          -  Healthy adult males or females between 18 and 55 years of age, inclusive.

          -  Female subjects must be of non-childbearing potential including pre-menopausal females
             with documented (medical report verification) hysterectomy or double oophorectomy or
             postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of
             spontaneous amenorrhea with serum FSH levels &gt; 40 mIU/mL or 6 weeks postsurgical
             bilateral oophorectomy with or without hysterectomy, or documented hysterectomy -
             tubal ligation is not sufficient

          -  Body weight &gt; 50 kg (110 pounds) and body mass index (BMI) between 19 and 31 where:

          -  Subjects with QTc &lt; 450 msec at screening (or QTc &lt; 480 msec for subjects with Bundle
             Branch Block).

          -  A signed and dated written informed consent prior to admission to the study

          -  The subject is able to understand and comply with protocol requirements, instructions
             and protocol-stated restrictions

        Exclusion Criteria:

          -  Any clinically relevant abnormality identified on the screening medical assessment,
             laboratory examination or ECG

          -  Systolic blood pressure &lt; 100 mmHg or ≥ 140 mmHg and/or diastolic blood pressure ≥ 90
             mmHg at the screening visit

          -  History of significant cardiac arrhythmias.

          -  Active peptic ulcer disease (PUD) and/or history of PUD

          -  Screening test positive for H. pylori at the screening visit

          -  History of gout and/or hyperuricemia

          -  A serum creatinine concentration above the reference range

          -  History of kidney stones

          -  PT and/or aPTT above the reference range

          -  History of recurrent indigestion, stomach upset or diarrhea

          -  Liver function tests (LFTs) or creatinine phosphokinase (CPK) above the normal
             reference range

          -  Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody within 3 months of
             screening

          -  Positive urine drug and alcohol screen at screening or predose on Day 1 of each period

          -  History of alcohol consumption exceeding, on average, 7 drinks/week for women or 14
             drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of
             hard liquor) within 6 months of the first dose of study medication or a positive
             alcohol test at screening

          -  History of use of tobacco or nicotine containing products within 6 months of screening
             or a positive urine cotinine screen

          -  Use of antimicrobials, proton pump inhibitors and bismuth containing medications
             within 2 weeks prior to testing for H. pylori at Screening

          -  Use of prescription (including hormone replacement therapy) or non-prescription drugs
             and vitamins within 7 days or 5 half-lives (whichever is longer) prior to
             administration of study medication. Use of prescription antibiotics within 14 days
             prior to administration of study medication. An exception is acetaminophen which is
             allowed at doses of &lt; 2g/day

          -  Use of dietary/herbal supplements including (but not limited to) St. John's wort,
             kava, ephedra (ma huang), gingko biloba, DHEA, yohimbe, saw palmetto, ginseng and red
             yeast rice within 14 days prior to treatment with study medication

          -  The subject has participated in a clinical trial and has received a drug or a new
             chemical entity within 30 days or 5 half-lives, or twice the duration of the
             biological effect of any drug(whichever is longer) prior to the first dose of current
             study medication

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the physician responsible,
             contraindicates their participation

          -  Consumption of grapefruit or grapefruit juice within 7 days prior to the first dose of
             study medication

          -  Donation of blood in excess of 500 mL within 56 days prior to dosing

          -  Unwillingness of male subjects to use a condom/spermicide, in addition to having their
             female partner use another form of contraception, such as an IUD, diaphragm with
             spermicide, oral contraceptives, injectable progesterone, subdermal implants or a
             tubal ligation, if engaging in sexual intercourse with a female partner who could
             become pregnant. This criterion must be followed from the time of the first dose of
             study medication until 84 days after the last dose of study medication

          -  Pregnant or nursing women

          -  History of other than rare (once yearly or less) flushing, particularly in
             perimenopausal women

          -  A hemoglobin A1c above the normal reference range and/or fasting blood glucose ≥100
             mg/dL at the screening visit

          -  History of intra-ocular pathology, including but not limited to retinitis, uveitis,
             retinal detachment and macular edema
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2007</study_first_submitted>
  <study_first_submitted_qc>October 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2007</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK256073A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

